drugset / Trial / NCT05239806
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged ≥12 Years Previously Fully Vaccinated With Inactivated COVID-19 Vaccine
RandomizedParallel-groupTriple-blindPrevention
Summary
The objective of study is to evaluate the immunogenicity and safety of SCTV01C or SCTV01E as booster compared with Sinopharm inactivated COVID-19 vaccine as booster. The study will also evaluate the immunogenicity and safety of 2-dose vaccinations.
Timeline
- Start
- 2022-04-01
- Primary completion
- 2022-08-01
- Completion
- 2023-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | BNT162b2 | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | SCTV01C | Vaccine | — | Intramuscular |
| Subject | SCTV01E | Vaccine | — | Intramuscular |
| Comparator | Sinopharm inactivated COVID-19 vaccine | Vaccine | — | Intramuscular |